

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-2978
WWW.FULBRIGHT.COM

CLANDRUM@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3167

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598


June 8, 2009

Commissioner for Patents
Attention: Certificates of Correction Branch
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

June 8, 2009
Date


Charles P. Landrum

RE: *Request for Certificate of Correction*
Patent No. 7,528,133 Dated: May 5, 2009
Application No. 10/069,744 Confirmation No.: 3491
Entitled: "CLINICAL USE OF THIAZOLIDINEDIONES ALONE OR IN
CONJUNCTION WITH OTHER AGENTS TO BLOCK OXYTOCIN-MEDIATED
ACTIONS SUCH AS UTERINE CONTRACTIONS IN PREMATURE LABOR OR
LACTATION" – John A. COPLAND III et al.
Our Ref.: UTSG:240US

Commissioner:

Attached is form PTO-1050. Errors of a minor nature are thereon corrected. The errors are due to Patent Office oversight. A Certificate of Correction is requested under 35 U.S.C. § 254.

It is believed that no fees under 37 C.F.R. §§ 1.16 to 1.21 are occasioned by the filing of this paper; however, should the Commissioner determine otherwise, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/UTSG:240US.

Very truly yours,



Charles P. Landrum

CPL/jst
Attachment

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,528,133
 DATED : May 5, 2009
 INVENTOR(S) : John A. COPLAND, III et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In title page, item (54) Title and in column 1, lines 1-4, delete

"USE OF THIAZOLIDINEDIONES DERIVATIVES FOR PREVENTING UTERINE CONTRACTIONS IN PREMATURE LABOUR OR LACTATION" and insert

--CLINICAL USE OF THIAZOLIDINEDIONES ALONE OR IN CONJUNCTION WITH OTHER AGENTS TO BLOCK OXYTOCIN-MEDIATED ACTIONS SUCH AS UTERINE CONTRACTIONS IN PREMATURE LABOR OR LACTATION--therefor.

In title page, item (57) Abstract, line 10, delete "Caesarian" and insert --Caesarean--therefor.

MAILING ADDRESS OF SENDER:
 Charles P. Landrum
 FULBRIGHT & JAWORSKI L.L.P.
 600 Congress Ave., Suite 2400
 Austin, Texas 78701

PATENT NO. 7,528,133
 No. of add'l. copies
 @ 50¢ per page

